Search Results

Hitachi Receives Order for Heavy Ion Therapy System from Shanghai Proton and Heavy Ion Center

Recently, Hitachi (China) Co., Ltd. received an order for one heavy ion cancer therapy system from the Shanghai Proton and Heavy Ion Center, and the two parties held a signing ceremony. This order is part of the Phase II construction project of the Shanghai Proton and Heavy Ion Center. Rendering of the completed Phase II project of the Shanghai Proton and Heavy Ion Center The Shanghai Proton and Heavy Ion Center is the first medical institution in China to possess both proton and heavy ion radiotherapy technologies. To further meet the demand for precision medicine, the center launched its Phase II construction in 2025, planning to add particle therapy system equipment. According to the project arrangement, the heavy ion therapy system ordered this time will be equipped with 4 treatment rooms and integrate Hitachi's moving-target tracking technology and pencil-beam scanning irradiation technology.

2026-08-24

South Korea Clarifies Statutory Functions of KAERI Radiation Injury Treatment Hospital

The Korea Atomic Energy Research Institute (KAERI) announced on August 24 that the National Assembly had passed a partial amendment to the Act on the Promotion of Radiation and Radioisotope Utilization at its plenary session on August 20, incorporating the functions of a radiation injury treatment hospital, along with supporting research and technology development, into the institute's statutory scope of business. Under the amendment, relevant institutions will provide specialized medical services to individuals who have sustained radiation injuries or are at risk of such injuries. Radiation injury generally refers to health abnormalities in the human body resulting from excessive exposure to radiation. Such injuries may not manifest immediately after exposure; even when early symptoms appear only as skin redness, they can later progress to ulceration, necrosis, and affect the blood or bone marrow systems. Some individuals also require long-term follow-up to monitor for delayed health risks such as cancer.

2026-08-24

Iran Says Its Atomic Energy Organization's Medical Products Serve Over 1.5 Million Patients Annually

Mohammad Eslami, head of the Atomic Energy Organization of Iran, recently stated that more than 1.5 million patients in Iran use diagnostic and therapeutic products developed by the organization each year, and related medical products have also been exported to multiple countries. Eslami made these remarks at a ceremony held by Iran's nuclear industry to celebrate Physicians' Day. He said that promoting the application of advanced treatment methods is one of the key directions of Iran's scientific and technological development. The progress made by Iranian researchers in cold plasma technology has opened up a "brand-new and promising path" for medical applications. He stated that plasma technology has not only achieved notable results in the research field but has also played a role in healthcare settings.

2026-08-24

Radexel leads South Korea's KRW 35.2 billion project to develop magnetically controlled radiotherapy equipment

South Korean medical device company Radexel announced on August 24 that it has been selected as the lead institution for a global flagship project, partnering with Asan Medical Center, the Korea Atomic Energy Research Institute (KAERI), and other organizations to develop next-generation radiotherapy equipment based on magnetic field control. The project is a national strategic R&D initiative jointly promoted by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety, with a total investment of KRW 35.2 billion, including KRW 27.95 billion in government funding, over a seven-year period. Under the plan, the Radexel consortium will develop a Magnetically Controlled Radiotherapy (MPRT) system. This technology controls secondary...

2026-08-24

Atom High-Tech Adds New Radiopharmaceutical Production Base in Changchun

The Jilin Provincial Medical Products Administration issued a public notice on August 21 stating that, in accordance with the Drug Administration Law of the People's Republic of China, the Regulations on the Administration of Radiopharmaceuticals, the Measures for the Supervision and Administration of Drug Production, and other relevant provisions, following on-site inspection and review approval, it intends to issue the Radiopharmaceutical Production License to Changchun Atom High-Tech Pharmaceutical Co., Ltd. The public notice period is 5 working days, subject to public supervision. The notice information shows that the registered address of Changchun Atom High-Tech Pharmaceutical Co., Ltd. is located at No. 770 Shengye Road, Beihu Science and Technology Development Zone, Changchun City, Jilin Province, and the proposed production address for the license is consistent with the registered address. The proposed production scope for this license is small-volume injections for in vivo radiopharmaceuticals, involving products such as Sodium Pertechnetate [99mTc] Injection, Technetium [99mTc] Methylenediphosphonate Injection, Technetium [99mTc] Methoxyisonitrile Injection, Technetium [99mTc] Pentetate Injection, Technetium [99mTc] Ethyl Cysteinate Dimer Injection, and Technetium [99mTc] Etifenin Injection.

2026-08-24

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

CNNC Particle and Beijing Institute of Medical Device Testing Carry Out Joint Learning and Co-building Activity

On August 20, CNNC Particle and the Beijing Institute of Medical Device Testing carried out a joint learning and co-building activity. Representatives from both sides engaged in in-depth discussions on topics such as Party building leading business development, joint development of technical standards, and enhancement of inspection and testing capabilities. Wu Wei, Secretary of the Party Branch and Director of CNNC Particle, Wu Kechun, Deputy Secretary of the Party Committee of the Institute, and more than twenty Party member representatives from both sides participated in the event. At the beginning of the event, the CNNC Particle delegation visited the Institute's laboratories to gain first-hand understanding of its technical capabilities and research progress in inspection and testing. The Institute's advanced experimental platforms and technologies left a deep impression on the visitors. During the discussion session, Wu Kechun and Wu Wei delivered speeches respectively. Both sides...

2026-08-22

Cubresa Brain PET Scanner Receives FDA 510(k) Clearance, Integrates with Existing PET/MR Systems

Molecular imaging technology company Cubresa Inc. announced on August 20 that its Cubresa BrainPET™ scanner has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). According to the company, the Cubresa BrainPET™ is a positron emission tomography (PET) device specifically designed for brain imaging and can be integrated into existing Siemens Biograph mMR MR/PET systems. The device enables healthcare institutions to perform simultaneous PET/MR brain imaging on existing MRI infrastructure, capturing molecular and anatomical information without the need to purchase a separate whole-body hybrid imaging system. Cubresa founder and CEO James ...

2026-08-22

South Korea's Asan Medical Center Develops AI-Based Radiopharmaceutical Therapy Platform with U.S. Institutions

The research team at Asan Medical Center in Seoul announced on the 21st that it has recently been selected for the "2026 Korea-U.S. Innovative Outcomes R&D New Support Project" organized by the Ministry of Health and Welfare, and will collaborate with U.S. research institutions to develop an artificial intelligence-based radiopharmaceutical therapy platform aimed at exploring new treatment strategies for solid tumors that respond poorly to conventional therapies. The team is composed of professors including Myung Seung-jae from the Department of Gastroenterology, Oh Seung-jun from the Department of Nuclear Medicine, Ryu Chang-hoon from the Department of Oncology, Jung Byung-kwan from the Department of Pathology, and Son Byung-ho from the Department of Breast Surgery at Asan Medical Center. The project will combine Asan Medical Center's large-scale clinical and pathological data, Emory University's AI-based digital pathology analysis technology, and Case Western Reserve University and University Hospitals Cleveland Medical Center's pathological and clinical research capabilities.

2026-08-22

Indiana University Health Establishes Center of Excellence in Theranostics to Advance Precision Targeted Cancer Therapy

Indiana University Health is establishing a new Center of Excellence in Theranostics, planning to provide cancer patients with more personalized diagnostic and treatment services through theranostic technologies. The project combines advanced medical imaging, precision diagnostics, and image-guided targeted therapy, aiming to enhance access to relevant medical services for patients in Indiana. Partial funding comes from a $20 million donor contribution, with Indiana University providing matching funds to bring total donations to $40 million. According to Indiana University, theranostics is a technological approach that integrates diagnosis and treatment. Clinically, advanced imaging techniques are first used...

2026-08-23

Global PET Market Expected to Reach $2.81 Billion by 2035, PET-CT Remains Dominant

A market research report shows that the global Positron Emission Tomography (PET) market size is expected to increase from $1.86 billion in 2025 to $2.81 billion by 2035, with a compound annual growth rate (CAGR) of 4.26% from 2026 to 2035. Increased demand for cancer diagnosis, expanded application of hybrid imaging technologies such as PET-CT and PET-MRI, and continued development of molecular imaging technologies are considered major factors driving market growth. The report notes that PET scans are being increasingly used in scenarios such as cancer detection and treatment evaluation, cardiac disease assessment, and diagnosis of neurological and psychiatric disorders. Meanwhile, population aging, rising healthcare expenditures, and growing demand for early screening are also driving...

2026-08-23

Construction of Radiotherapy and Radiosurgery Center Completed at Bulgaria's St. Ivan Rilski University Hospital

All construction and repair work for the new Radiotherapy and Radiosurgery Center at Bulgaria's St. Ivan Rilski University Hospital has been fully completed. According to the hospital, a latest-generation medical linear accelerator has been installed in the center, capable of sub-millimeter patient positioning accuracy. The equipment was delivered by the Ministry of Health under the National Recovery and Resilience Plan, as part of the investment project for the modernization of the national system for diagnosis and treatment of oncological diseases, funded by the European Commission's Recovery and Resilience Facility. The device is a TrueBeam-EDGE linear accelerator manufactured by Varian Medical Systems, equipped with BrainLab's ExactTrac Dynamic system, valued at 5.1 million...

2026-08-21

Five New Oncology Diagnostic and Treatment Devices at Bulgaria's ISUL Hospital Expected to Launch This Autumn

Queen Joanna - ISUL University Hospital in Bulgaria expects to begin operating five new devices for imaging diagnosis and treatment of oncological diseases starting early this autumn. The hospital stated that patients will be able to use these high-tech devices after the relevant licensing and approval procedures are completed. Source: Queen Joanna University Hospital - ISULThe newly added equipment is deployed in the imaging diagnostics department and the radiation oncology department. Among them, the radiation therapy department will be equipped with a TrueBeam v4.1 medical linear accelerator, primarily used for radiotherapy and radiosurgery. This device can deliver high-energy radiation to tumor tissue with greater precision, supporting high-precision dose planning to achieve the required therapeutic effect while minimizing radiation exposure to healthy tissues and organs surrounding the tumor.

2026-08-21

South Korea's National Assembly Passes Amendments on Radiation Disaster Response, Strengthening the Treatment System for Radiation Victims

The South Korean National Assembly held a plenary session on the 20th and passed two livelihood bills proposed by Rep. Yoon Jun-byeong, a member of the Parliamentary Agriculture, Food, Rural Affairs and Fisheries Committee. The bills concern the establishment of a radiation disaster response system and adjustments to the support system for surviving family members of national meritorious persons. Under the amendments passed, the Korea Atomic Energy Research Institute will be granted the qualification to operate as a specialized hospital for treating radiation victims. This arrangement aims to further improve the national medical safety net, enabling industrial radiation workers and victims of accidental radiation incidents to receive faster and more systematic treatment and rehabilitation support. Meanwhile, another amendment was also passed. This amendment, in accordance with the Constitutional Court's ruling of nonconformity, abolishes the provision that prioritized age as the sole criterion in the payment of survivor benefits to families of national meritorious persons of the same rank. After the relevant institutional adjustment, greater emphasis will be placed on safeguarding the rights of low-income households to reduce blind spots in welfare support.

2026-08-21

Iran Restarts Cyclotron to Boost Supply of Radiopharmaceuticals for Cancer Diagnosis and Treatment

Iranian nuclear industry experts have recently resumed operation of a cyclotron used in nuclear medicine, which can produce radioisotopes needed for cancer diagnosis and treatment. According to plans, by the end of Iran's Seventh Development Plan, i.e., March 2029, Iran will have seven such centers to expand domestic supply capacity for medical radioisotopes. A cyclotron is a type of particle accelerator that can be used to produce nuclear medicine radioisotopes and further prepare radiopharmaceuticals. These drugs can be used for the detection, diagnosis, and monitoring of malignant tumors. Data shows that related products produced domestically in Iran include FDG and F-PSMA, primarily serving nuclear medicine diagnosis and treatment for various cancers...

2026-08-21